Cargando…
Sorafenib inhibits macrophage-mediated epithelial-mesenchymal transition in hepatocellular carcinoma
Tumor-associated macrophages, crucial components of the microenvironment in hepatocellular carcinoma, hamper anti-cancer immune responses. The aim of the present study was to investigate the effect of sorafenib on the formation of the tumor microenvironment, especially the relationship between polar...
Autores principales: | Deng, Yan-Ru, Liu, Wen-Bin, Lian, Zhe-Xiong, Li, Xingsheng, Hou, Xin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5122390/ https://www.ncbi.nlm.nih.gov/pubmed/27203677 http://dx.doi.org/10.18632/oncotarget.9438 |
Ejemplares similares
-
Regorafenib reverses HGF‐induced sorafenib resistance by inhibiting epithelial‐mesenchymal transition in hepatocellular carcinoma
por: Chen, Weibo, et al.
Publicado: (2019) -
Sorafenib suppresses the epithelial-mesenchymal transition of hepatocellular carcinoma cells after insufficient radiofrequency ablation
por: Dong, Shuying, et al.
Publicado: (2015) -
Corrigendum to: Regorafenib reverses HGF‐induced sorafenib resistance by inhibiting epithelial‐mesenchymal transition in hepatocellular carcinoma
Publicado: (2022) -
SMYD3 induces sorafenib resistance by activating SMAD2/3-mediated epithelial-mesenchymal transition in hepatocellular carcinoma
por: Wang, Shanshan, et al.
Publicado: (2023) -
Apatinib inhibits macrophage-mediated epithelial–mesenchymal transition in lung cancer
por: Liu, Shuliang, et al.
Publicado: (2018)